Related Experiment Videos
Tumor models to investigate the therapeutic efficiency of immunomodulators
Abstract:
The development of successful approaches to immunotherapy is dependent on the proper consideration of the pathobiology of metastasis and a better understanding of the principles of biological response modification. Immunomodulation as a therapeutic modality has not proven notably effective in animals with preexistent palpable disease, an observation in agreement with the results from clinical protocols. Therefore, rather than developing experimental immunotherapy models of immunoprophylaxis or models with minimal tumor burden, we believe it more appropriate to develop models based on preexistent metastatic disease in a tumor-conditioned host. The most rigorous test of a biological response modifier's efficiency prior to clinical trials will be provided from immunotherapeutic trials of palpable autochthonous tumors.
Insights
Developing effective immunotherapy requires understanding metastasis and biological response modification. New models focusing on palpable, metastatic tumors offer a rigorous test for therapeutic strategies before clinical application.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Successful immunotherapy development hinges on understanding metastasis and biological response modification principles.
- Current immunomodulation therapies show limited efficacy in animals with existing palpable disease, aligning with clinical trial outcomes.
Purpose of the Study:
- To propose a shift from immunoprophylaxis or minimal tumor burden models.
- To advocate for developing experimental models that incorporate preexistent metastatic disease in a tumor-conditioned host.
Main Methods:
- The study emphasizes the need for rigorous testing of biological response modifiers.
- Recommends utilizing immunotherapeutic trials involving palpable autochthonous tumors.
Main Results:
- The abstract does not present specific results but outlines a proposed methodological approach.
Conclusions:
- Models based on preexistent metastatic disease provide a more stringent evaluation of immunotherapy efficacy.
- Testing biological response modifiers in palpable autochthonous tumors is crucial before human clinical trials.